Pain Associated With Head and Neck Cancer Photoimmunotherapy Authors: SHIGEKAZU YOSHIDA, ISAKU OKAMOTO, KUNIHIKO TOKASHIKI, KIYOAKI TSUKAHARA Published: 2026 ABSTRACT Background/AimHead and neck photoimmunotherapy (HN-PIT) achieves local control in unresectable locally advanced or recurrent head and neck cancer; however, acute post-treatment pain remains clinically important. This retrospective study evaluated pain timing and intensity, the association between a revised analgesic protocol and pain, the relationship between tumor diameter and pain, and adverse events after HN-PIT.Patients and MethodsPatients who underwent HN-PIT at Tokyo Medical University Hospital between February 2021 and November 2025 were reviewed. Pain outcomes were analyzed in 47 patients during the first HN-PIT cycle; adverse events were evaluated in 48 patients, including one excluded from pain assessment because of intubation. Numerical Rating Scale (NRS) scores were recorded from illumination day to day 7, with the highest score defined as maximum NRS. Maximum NRS scores were compared between 2021-2023 and 2024-2025, before and after implementation of a multimodal analgesic protocol. Pearson’s correlation coefficient and simple linear regression assessed the relationship between maximum tumor diameter and maximum NRS. Adverse events were graded according to CTCAE v5.0.ResultsAmong 45 patients who experienced pain during the first week, 28 (62%) had peak NRS scores on illumination day. Maximum NRS was lower in 2024-2025 than in 2021-2023 (5.17±3.16 vs. 7.08±2.36). Maximum tumor diameter was not significantly associated with maximum NRS. Among 48 patients evaluated for adverse events, pain (97.9%), mucositis (70.8%), and laryngeal edema (58.3%) were most common.ConclusionPain after HN-PIT peaked on illumination day. A standardized multimodal analgesic protocol was associated with reduced pain intensity. Tumor diameter was not a major pain severity determinant. Introduction Head and neck photoimmunotherapy (HN-PIT) has recently emerged as a treatment option for head and neck cancer (1). HN-PIT uses an antibody-photoabsorber conjugate consisting of cetuximab, a chimeric anti-human epidermal growth factor receptor (EGFR) monoclonal antibody (IgG1), linked to the photosensitizer IR700. Illumination with 690-nanometer red light selectively destroys cancer cells bound to the conjugate, enabling local control that is difficult to achieve with conventional treatments (2-4). Preclinical studies show tumor shrinkage in non-illuminated lesions through immune activation, known as the abscopal effect (5, 6). The first clinical development of this treatment was conducted in patients with head and neck cancer (7, 8). Cetuximab sarotalocan sodium, an anti-EGFR antibody conjugated with IR700, exerts antitumor activity after intravenous administration followed by 690-nanometer red-light illumination 20 to 28 h later. In Japan, the drug and related medical devices were approved in 2020 for unresectable locally advanced or recurrent head and neck cancer under the Sakigake Designation System and Conditional Early Approval System. This approval represented an important step toward expanding clinical use and treatment options for patients. If residual tumor remains, treatment can be repeated up to four times at intervals of at least four weeks. As HN-PIT was introduced under conditional early approval, real-world evidence on complications remains limited beyond preclinical studies and clinical trials. Adverse events requiring close monitoring include carotid artery and tumor hemorrhage, tongue swelling, laryngeal edema, infusion reactions, fistulas, skin and mucosal ulcers or necrosis, photosensitivity, pain, skin disorders, and hypomagnesemia. Clinical reports have described laryngeal edema requiring emergency tracheostomy after HN-PIT (9) and Lemierre’s syndrome (10); however, pain management is particularly important in the acute phase (11). Inadequately controlled acute pain can cause hyperglycemia, insulin resistance, increased infection risk, reduced patient comfort and satisfaction, and chronic pain (12-14). Pain associated with HN-PIT often occurs immediately after treatment and is thought to result from cancer cell membrane disruption induced by the interaction between the photosensitizer and light illumination (8). A more detailed understanding of this pain mechanism is expected to facilitate development of more effective pain management strategies. To date, large-scale real-world data on pain after HN-PIT have been limited, with most published reports involving small cohorts. The objective of this study was to retrospectively analyze the onset, intensity, and duration of pain in clinical practice, exploring improved pain management strategies. Patients and Methods Patients. This study included patients with unresectable locally advanced or locally recurrent head and neck cancer who underwent HN-PIT at Tokyo Medical University Hospital between February 1, 2021, and November 30, 2025. Although HN-PIT can be administered repeatedly, only the initial treatment cycle was included in the pain assessment to ensure consistency. Patients managed with endotracheal intubation after HN-PIT were excluded because pain assessment was not feasible. Patients who declined participation were also excluded. Methods. The primary endpoint was the difference in maximum Numerical Rating Scale (NRS) scores between the 2021-2023 and 2024-2025 treatment periods. Secondary endpoints included the association between pre-treatment maximum target tumor diameter and maximum NRS during the first HN-PIT cycle, and incidence and severity of adverse events (AEs). Pain was assessed using the NRS, a tool routinely used in clinical practice (15). The NRS is an 11-point scale ranging from 0 (no pain) to 10 (worst possible pain). NRS values recorded from the day of the first HN-PIT cycle through day 7 after illumination were retrospectively collected from medical records. The highest recorded NRS value was defined as the maximum NRS. Pain was self-assessed by patients 3 h after illumination on the day of illumination and at 8:00 a.m. on days 1-7 after illumination. For peri-illumination pain management, all patients received steroids for anti-inflammatory purposes and intravenous patient-controlled analgesia (IV-PCA) (16). Given that our institutional pain management protocol was revised in 2024 (Table I), patients were grouped according to treatment period: 2021-2023 or 2024-2025. In the 2021-2023 group, analgesic administration after IV-PCA completion was determined by the attending physician without a standardized protocol. In the 2024-2025 group, post-HN-PIT pain management was standardized with immediate post-illumination local anesthetic administration (bupivacaine hydrochloride hydrate) and multimodal analgesia. Maximum NRS was compared between the two treatment-period groups. Maximum target tumor diameter at illumination was measured using computed tomography (CT) or magnetic resonance imaging (MRI) performed immediately beforehand. When CT or MRI measurement was difficult because of superficial lesions, tumor diameter was measured endoscopically on the illumination day. For patients with multiple target lesions, the largest target lesion diameter was used to examine the relationship between tumor size and maximum NRS. Other AEs were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, which classifies severity from mild to death-related events (17). Table IPain management protocol according to head and neck photoimmunotherapy treatment period.IV-PCA: Intravenous patient-controlled analgesia; NSAIDs: nonsteroidal anti-inflammatory drugs. Pain management protocol according to head and neck photoimmunotherapy treatment period. IV-PCA: Intravenous patient-controlled analgesia; NSAIDs: nonsteroidal anti-inflammatory drugs. For HN-PIT, cetuximab sarotalocan sodium (Akalux® IV Infusion 250 mg; Rakuten Medical Japan K.K., Tokyo, Japan) was administered intravenously, followed by 690-nanometer red-light illumination of the target tumor 20-28 h later. Illumination was delivered using a photodynamic therapy semiconductor laser system, BioBlade® Laser System, with BioBlade® Cylindrical Diffuser, BioBlade® Frontal Diffuser, BioBlade® Side-Fire Diffuser, and BioBlade® Needle Catheter (Rakuten Medical Japan K.K., Tokyo, Japan). Statistical analyses. To compare pain management before and after protocol revision, the maximum NRS was compared between the 2021-2023 and 2024-2025 groups using Welch’s two-sample t-test (two-tailed). The Mann-Whitney U test (two-tailed) was performed as a sensitivity analysis. To evaluate the relationship between maximum NRS during the first week after illumination (days 0-7) and maximum target tumor diameter, a scatter plot was generated. Pearson’s correlation coefficient (r) was calculated to assess linear correlation. Simple linear regression analysis was performed to calculate the coefficient of determination (R2). Statistical significance was assessed using a two-sided p-value with a significance threshold of 0.05. Statistical analyses were performed using IBM SPSS Statistics software, version 31.0 (IBM Corp., Armonk, NY, USA). Ethics. This study was approved by the Tokyo Medical University Ethics Committee (approval No. T2022-0120). All procedures were conducted in accordance with the Declaration of Helsinki. Written or opt-out consent was obtained from each patient. Results Patient characteristics. During the study period, 49 patients with unresectable locally advanced or locally recurrent head and neck cancer underwent HN-PIT at Tokyo Medical University Hospital. Of these, 47 patients were included in the analysis after excluding one patient owing to post-HN-PIT endotracheal intubation that prevented pain assessment and one patient whose first treatment cycle occurred before the study period, although the second cycle occurred within the study period. Patient characteristics are summarized in Table II. The median age was 64 years, 35 patients (74%) were male, and all had an ECOG performance status of 0 or 1. Fifty target lesions were evaluated because some patients had multiple lesions. The oropharynx was the most common target site. All patients had a history of surgery or radiation therapy. Maximum tumor diameter ranged from 7 to 77 mm. Twenty-six patients (55%) experienced severe pain, defined as NRS ≥7. Peak NRS most frequently occurred on the illumination day (day 0), observed in 28 of 45 patients (62%) after excluding two patients who reported no pain during the first week post-illumination. Table IIPatient characteristics.PS: Performance status. Patient characteristics. PS: Performance status. The maximum NRS according to HN-PIT treatment period was 7.08±2.36 (median, 8; range=2-10) in the 2021-2023 group (n=24) and 5.17±3.16 (median, 5; range=0-10) in the 2024-2025 group (n=23). Welch’s two-sample t-test showed that the maximum NRS was significantly lower in the 2024-2025 group than in the 2021-2023 group [mean difference, 1.91 (2021-2023 minus 2024-2025); 95% confidence interval=0.26-3.56; p=0.0242]. The Mann-Whitney U test, performed as a sensitivity analysis, also showed a significant difference (p=0.026). A scatter plot of maximum NRS and maximum target tumor diameter for each patient (Figure 1) demonstrated a weak, non-significant linear correlation (r=-0.116, R2=0.0135; p=0.437). Association between maximum tumor diameter and maximum Numerical Rating Scale score after head and neck photoimmunotherapy. Scatter plot showing association between maximum tumor diameter and maximum Numerical Rating Scale (NRS) score after the first cycle of head and neck photoimmunotherapy. No significant linear correlation was observed between maximum tumor diameter and maximum NRS. Table III summarizes all AEs. AE analysis included 48 patients, including one patient excluded from pain assessment owing to post-illumination endotracheal intubation. Pain was the most frequently observed AE, with Grade 3 pain occurring in nine patients (18.8%) overall. By treatment period, Grade 3 pain was observed in five patients (20.8%) in the 2021-2023 group (n=24) and in four patients (16.7%) in the 2024-2025 group (n=24). Apart from pain, mucositis, laryngeal edema, hemorrhage, and dysphagia were relatively common AEs. Grade 4 laryngeal edema was observed in four patients (8.3%). No Grade ≥3 hemorrhage was observed. No Grade 5 events occurred. Table IIIAdverse events. Adverse events. Discussion Pain after HN-PIT is clinically important because it occurs acutely after illumination, may substantially impair patient comfort and quality of life, and remains insufficiently characterized in real-world clinical practice. In this retrospective study, pain after HN-PIT most frequently peaked on the illumination day, and the maximum NRS was significantly lower after implementation of a standardized multimodal analgesic protocol in 2024-2025 than in 2021-2023. In contrast, maximum tumor diameter was not significantly associated with maximum NRS, suggesting that post-HN-PIT pain is not determined solely by tumor size. These findings indicate that immediate peri-illumination pain control is essential and that standardized multimodal analgesia may improve acute pain management after HN-PIT. This study is, to our knowledge, the largest real-world analysis to date specifically focused on pain after HN-PIT. When stratified by treatment period, the 2024-2025 group had significantly lower maximum NRS than the 2021-2023 group. This suggested that updating the pain management strategy based on accumulated clinical experience during the first three years after HN-PIT introduction may have improved pain control. However, the incidence of Grade 3 pain did not clearly differ between the two periods, and further investigation is needed to determine whether the revised pain management strategy reduces severe pain. Although larger tumor diameter was hypothesized to increase pain owing to wider illumination fields, no significant correlation was observed between maximum tumor diameter and maximum pain intensity. This study is clinically relevant because it retrospectively evaluated pain timing, intensity, and temporal course, and examined a feasible pain management strategy in routine practice. Patient suffering includes physical, psychological, and social distress, with pain representing a major burden that reduces quality of life (QOL) (18). Patients with head and neck cancer often experience functional impairments such as voice and swallowing disorders, in addition to persistent tumor-related pain; therefore, holistic care addressing total suffering is essential. Multidisciplinary head and neck cancer treatment is associated with a high incidence of pain owing to various adverse reactions, including inflammation of the oral and pharyngeal mucosa and postoperative pain (19, 20). In this study’s AE analysis, pain occurred in 97.9% of patients, with Grade 3 pain in 18.8%. Poorly controlled pain can reduce QOL and may cause treatment delays or interruptions, making effective pain management essential. Pain is classified as nociceptive or neuropathic; nociceptive pain includes somatic and visceral subtypes. Somatic pain results from injury or inflammation in somatic tissues, including skin, muscle, and bone. Neuropathic pain results from damage or disease of the somatosensory nervous system. In head and neck cancer, neuropathic pain may occur because of the dense distribution of critical anatomical structures near the body surface. In HN-PIT, rapid destruction of IR700-bound tumor cells after illumination leads to irreversible morphological changes (3), suggesting a predominantly somatic nociceptive mechanism. As tumor cells are rapidly destroyed, pain is thought to peak immediately after illumination or within approximately 1 h, then decrease by the following day (11). In this study, peak pain most often occurred on day 0 when assessed 3 h after illumination, indicating an early peak on the illumination day. These findings supported the need for integrated prophylactic, multimodal, and individualized analgesic strategies to address the immediate onset of post-treatment pain. According to WHO cancer pain guidelines, the analgesic ladder should be considered an educational tool rather than a strict protocol, with drug selection guided by pain intensity (21). For moderate to severe pain, long-term low-dose morphine has been shown to provide greater pain relief than tramadol (22). Adjunctive analgesics, including anticonvulsants, antidepressants, corticosteroids, benzodiazepines, and phenothiazines are useful for neuropathic pain management (23). Multimodal pain management, including preventive analgesia, non-opioid agents, opioid analgesics, and adjuvant analgesics, is central to managing acute pain peaks (24). Multimodal pain management combines medications and interventions with different mechanisms of action to improve analgesia, patient comfort, and overall treatment outcomes (25). In this study, maximum NRS was significantly lower in 2024-2025, suggesting an association with the introduction of multimodal pain management. The institutional protocol includes intravenous steroid administration at illumination onset, followed by local bupivacaine hydrochloride hydrate injection at the illumination site immediately after treatment. Post-illumination management includes IV-PCA for approximately 24-48 h starting on the illumination day, along with nonsteroidal anti-inflammatory drugs, acetaminophen, and low-dose opioids from day 0 to day 5. Low-dose opioids are discontinued from day 6 onward. Although HN-PIT achieves local control without compromising QOL (26), appropriate pain control is essential for improving patient satisfaction, QOL, and overall treatment outcomes. In this study, the main AEs other than pain were mucositis (70.8%), laryngeal edema (58.3%), hemorrhage (54.2%), and dysphagia (39.6%). Although no Grade ≥4 mucositis was observed, previous reports have described progression from Grade 1 mucositis to Grade 5 sepsis (27), necessitating careful monitoring until mucositis resolves. Laryngeal edema is also a frequent AE, and cases of Grade 4 laryngeal edema requiring emergency tracheostomy after illumination have been reported (9). At this institution, prophylactic tracheostomy is concurrently performed during illumination except in patients with a permanent tracheostoma or nasopharyngeal cancer. Patients who decline tracheostomy are managed in the intensive care unit with post-illumination endotracheal intubation. Grade 2 hemorrhage requiring blood transfusion occurred in 14.6% of patients, highlighting the need for careful post-illumination monitoring using visual inspection and endoscopy, similar to laryngeal and facial edema surveillance. Dysphagia was also common (39.6%), including Grade 3 dysphagia in 14.6% of patients. When dysphagia occurs alongside pain and mucositis, it can readily lead to reduced oral intake, dehydration, and malnutrition, warranting swallow assessment and early nutritional support. These AEs can prolong hospitalization, reduce QOL, and ultimately hinder transition to subsequent treatment, making early intervention necessary. In recurrent head and neck cancer, sequential use of limited treatment options may contribute to prolonged survival. A complete response to pembrolizumab after disease progression following HN-PIT has been reported (28), emphasizing the importance of transitioning to subsequent treatment without compromising QOL. In this context, appropriate management of acute post-HN-PIT adverse events may have clinical implications beyond symptom relief. A previous feasibility study of NIR-PIT combined with immune checkpoint inhibitor therapy reported that subsequent immune checkpoint inhibitor therapy could be administered without immune-related adverse events or worsening of prior Grade 3 adverse events after NIR-PIT (29). These findings suggest that maintaining QOL and general condition after HN-PIT may be important for preserving subsequent systemic treatment options, including immune checkpoint inhibitors. Therefore, optimal pain management after HN-PIT may contribute not only to short-term patient comfort but also to broader treatment sequencing in patients with unresectable locally advanced or recurrent head and neck cancer. Limitations. First, it is a single-center retrospective study with a limited sample size. Second, patient backgrounds were heterogeneous, including differences in prior surgery. Third, measurement methods for target tumor diameter were not fully standardized. Future studies should include larger patient cohorts and should comprehensively evaluate both objective and subjective pain outcomes. Development of standardized pain assessment tools specific to HN-PIT may improve pain management by enabling more precise evaluation of multimodal analgesic strategies. Conclusion This study provides clinically relevant evidence on pain after HN-PIT and highlights the need for an integrated pain management approach. Findings suggest that prophylactic analgesia and multimodal pain management may improve patient comfort and QOL. The absence of a significant linear correlation between maximum tumor diameter and pain intensity suggests that post-HN-PIT pain mechanisms are complex and multifactorial. Future multicenter prospective studies with standardized pain assessment, analgesic protocols, and evaluation of patient-reported outcomes are warranted to clarify the mechanisms of post-HN-PIT pain and to establish optimal pain management strategies. Conflicts of Interest The Authors declare no conflicts of interest in relation to this study. Authors’ Contributions Shigekazu Yoshida: Conceptualization, data curation, formal analysis, investigation, visualization, writing - original draft. Isaku Okamoto: Conceptualization, methodology, supervision, writing - review and editing. Kunihiko Tokashiki: Investigation, resources, writing - review and editing. Kiyoaki Tsukahara: Supervision, project administration, writing - review and editing. Artificial Intelligence (AI) Disclosure During the preparation of this manuscript, a large language model (ChatGPT; OpenAI) was used solely for language editing and stylistic improvements in select paragraphs. No sections involving the generation, analysis, or interpretation of research data were produced by generative AI. All scientific content was created and verified by the authors. Furthermore, no figures or visual data were generated or modified using generative AI or machine learning-based image enhancement tools. The authors used ChatGPT (OpenAI) to assist with English language editing, grammar checking, wording refinement, and formatting checks according to the journal instructions. The AI tool was not used for study conception, data collection, data analysis, statistical interpretation, generation of scientific conclusions, or reference selection. All AI-assisted text was critically reviewed, edited, and approved by the authors, who take full responsibility for the content of the manuscript.